Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies.

Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies. Cancer. 2004 Sep 01; 101(5):1072-80.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.